DocNoirII: HPV‑negative HSIL needs retest

A Pap result showing HSIL is one of the more serious cervical screening findings. It means the lab saw cells that look strongly suspicious for a high-grade precancer. The confusing part is when the HPV test comes back negative at the same time. That sounds reassuring, but turns out it does not cancel the Pap result. Current U.S. guidance still treats HPV-negative HSIL as a finding that needs prompt diagnostic follow-up, not a shrug and a repeat years later. ### What does HSIL actually mean? HSIL stands for high-grade squamous intraepithelial lesion. On a Pap test, that is cytology language — basically, what the cells look like under the microscope. It is not the same thing as a biopsy diagnosis, but it is meant to flag a meaningful risk of CIN2, CIN3, or worse, which are the precancer categories clinicians are trying to catch before cancer develops. (acog.org) ### Why doesn’t a negative HPV test settle it? Because the HPV test and the Pap test answer different questions. HPV testing looks for high-risk viral material in the sample. Cytology looks for abnormal cell changes. A negative HPV result lowers risk in many low-grade situations, but it does not prove the cervix is normal when the cytology already looks high-grade. False-negative HPV results happen. Sampling issues happen. And HPV can sometimes reactivate or be missed even when biologic damage is already present. (cancer.gov) ### So what do the guidelines say? The practical answer is straightforward: HPV-negative HSIL still goes to colposcopy, and in some nonpregnant patients 25 or older, treatment without a preceding biopsy can still be an acceptable option depending on the full risk picture. The CDC’s summary table of the ASCCP guidelines puts “negative HSIL” in the “colposcopy or expedited treatment” category, not in routine surveillance. ACOG also endorses the ASCCP risk-based framework that uses current results plus prior history to decide next steps. (cancer.gov) ### Why not just repeat the HPV test and move on? You can repeat testing, but not as a substitute for evaluating the cervix. The point of repeat HPV testing or cotesting is to clarify the picture, not to overrule a high-grade Pap by itself. If the Pap says HSIL, clinicians still need to look directly with colposcopy and usually biopsy any suspicious areas, because management depends on whether tissue confirms precancer. (cdc.gov) ### What does colposcopy add? Colposcopy is the bridge from screening to diagnosis. It lets the clinician inspect the cervix under magnification, apply acetic acid, and target biopsies to the abnormal areas. That matters because treatment decisions are made from histology — what the biopsy shows — not from the Pap alone. If biopsy shows CIN2 or CIN3, excisional treatment like LEEP may be recommended. If biopsy does not confirm high-grade disease, follow-up can look very different. (acog.org) ### Why is clinicopathologic correlation such a big deal? Because this is exactly the kind of mismatch that can fool people. One test says “high-grade.” Another says “HPV not detected.” The safe move is to reconcile the mismatch, not pick the more comforting answer. Cytology, HPV testing, colposcopic impression, biopsy, and prior screening history all matter together in the ASCCP system. (acog.org) ### Does this mean the HPV test failed? Not necessarily. It means screening is probabilistic, not magical. HPV tests are extremely useful, but they are not perfect rule-out tools in every scenario. A high-grade cytology result is one of the scenarios where the abnormal cells themselves carry enough weight that clinicians still have to chase the finding. ### Bottom line? (acog.org) If someone has HSIL on a Pap and the HPV test is negative, the important message is not “good news, ignore it.” It is “this mismatch needs workup.” The usual next step is prompt colposcopy, often with repeat testing as part of the evaluation, because only tissue can tell whether this is true precancer and what treatment — if any — should come next. (cancer.gov)